... WhatsApp

Adding Durvalumab to BCG Improves Bladder Cancer Outcomes

You are here >> Home > Latest Updates > Urinary Bladder Cancer > Adding Durvalumab…

Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC) final analysis of a randomised DOI 10.1016S0140-6736(25)01897-5

Bladder cancer often comes back even after standard treatments. For patients with high-risk non-muscle-invasive bladder cancer (NMIBC) who haven’t had BCG before, new options are being tested to keep the cancer from returning.

This study looked at whether adding a drug called durvalumab to BCG could help. Durvalumab helps the immune system find and fight cancer cells. Over 1,000 patients took part in the trial. All had surgery to remove the bladder tumor before starting treatment.

Patients were split into three groups. One group got BCG alone. Another group got BCG plus durvalumab for a short time. The third group got BCG with durvalumab for a full year.

After five years, the group that got a full year of both treatments did the best. They had fewer cancer recurrences and were less likely to die. The risk of cancer coming back or death dropped by 32% compared to BCG alone.

Some patients had side effects, mostly from the immune-boosting drug, but no treatment-related deaths were reported.

This study shows that combining BCG with durvalumab for one year may be a better way to treat high-risk NMIBC for people who haven’t had BCG before.

If you’re starting treatment for this type of bladder cancer, ask your doctor about this new option.

Rate this post

Exclusive Health Tips and Updates

dr swati shah - uro & gynec cancer surgeon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.